(NASDAQ: MIST) Milestone Pharmaceuticals's forecast annual revenue growth rate of 321.67% is forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 33.6%, and it is also forecast to beat the US market's average forecast revenue growth rate of 14.06%.
Milestone Pharmaceuticals's revenue in 2026 is $1,546,000.On average, 8 Wall Street analysts forecast MIST's revenue for 2026 to be $4,555,959,298, with the lowest MIST revenue forecast at $461,255,726, and the highest MIST revenue forecast at $10,316,478,511. On average, 8 Wall Street analysts forecast MIST's revenue for 2027 to be $3,474,008,686, with the lowest MIST revenue forecast at $2,421,592,561, and the highest MIST revenue forecast at $4,942,025,634.
In 2028, MIST is forecast to generate $16,638,152,968 in revenue, with the lowest revenue forecast at $6,572,894,093 and the highest revenue forecast at $35,360,193,411.